Viewing nowCombinationLitrazen Duo Tablet 2.5/850mg
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Weetus Pharmaceutical Co., Ltd.

MFDS item code 201908008 · Approved 2019.11.20 · Insurance code 660703840
Improves glycemic control in type 2 diabetes mellitus
This medication helps control blood sugar levels in patients with type 2 diabetes by using linagliptin and metformin together. When used along with dietary and exercise therapies, blood sugar can be managed more effectively. This helps stabilize blood sugar levels and aids in the prevention of complications of diabetes. Continuous use of this medication can significantly assist in blood sugar control.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of drug treatment for diabetes whose blood glucose cannot be adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients whose blood glucose cannot be adequately controlled with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose cannot be adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current dose of metformin. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with caution in the following patients). 5. Patients whose blood glucose cannot be adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current dose of metformin. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with caution in the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may cause a change in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dose adjustment, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, 2. Do not administer to the following patients).
This medication can cause a serious side effect called lactic acidosis due to one of its active ingredients, metformin hydrochloride. Lactic acidosis is a rare but very dangerous metabolic complication that occurs more frequently when there is a sudden deterioration in kidney function or in conditions such as cardiopulmonary disease or sepsis. In such situations, this medication must be stopped immediately, and symptoms should prompt an immediate visit to a hospital. This medication should not be administered to certain patients. For example, individuals with an allergy to any component of this medication, those with type 1 diabetes, lactic acidosis, diabetic ketoacidosis, severe renal impairment, liver dysfunction, acute myocardial infarction or in a state of shock, as well as women who are pregnant or breastfeeding should not use it. Additionally, due to the risk of hypoglycemia, caution is required when used concurrently with other hypoglycemic agents such as sulfonylureas or insulin, and dosage adjustments may be necessary if needed. Elderly patients or those taking medications that can affect renal function should undergo regular kidney function tests. Rare side effects such as acute pancreatitis or bullous pemphigoid may occur, so persistent and severe abdominal pain or skin blisters should be reported to a doctor immediately. This medication can lower vitamin B12 levels, so it is advisable to regularly check for vitamin B12 deficiency if taking it over a long period. There may also be interactions with other medications, so patients taking other drugs should inform their doctor or pharmacist, especially when used with drugs that can affect kidney function. Women who are pregnant or planning to become pregnant are advised to avoid this medication, and it should not be used while breastfeeding. Safety and efficacy have not been confirmed for children under 10 years old or for pediatric and adolescent patients aged between 10 and 17 years old, so it is not recommended. Elderly patients commonly experience reduced renal function, so they should regularly monitor their renal function and adjust the dosage accordingly when using this medication. When taking this medication, it should be stored out of reach of children, kept away from moisture, and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. The storage temperature should be maintained between 1°C and 30°C to preserve the medication's effectiveness for a longer period.
Bright orange colored oval coated tablet
60 tablets/box [10 tablets/PTP x 6]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Weetus Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.